Bristol Myers Squibb is striking a $15 billion drug licensing deal with China's Hengrui Pharma May 12, 2026 · The agreement covers 13 early-stage programs in oncology, hematology, and immunology, with $600 million due upfront Read more »
.png?branch=production&format=jpg&width=1024)
.jpg?branch=production&format=jpg&width=1024)
